Characteristics of studies and baseline variables of patients who underwent transcatheter aortic valve implantation included in this analysis
| First author | Year | Type of study | Type of prosthesis | Study period | Number of patients | Age | Mean STS score | Mean Logistic EuroSCORE | Coronary artery disease (%) | Prior CABG/cardiac surgery (%) | Prior PCI (%) | Peripheral vascular disease (%) | Cerebro- vascular disease (%) | Pulmonary disease (%) | LVEF (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdel-Wahab9 | 2012 | R, SC | CoreValve | 09.2007–03.2011 | 125 | 81.0±6.4 | – | 24.3±13.8 | 72.8 | 19.2 | 30.4 | 16.8 | 10.4 | – | 47.7±14.5 |
| Attias10 | 2010 | P, SC | SAPIEN /CoreValve | 10.2006–06.2009 | 83 | 81±9 | 15±8 | 26±14 | 50.6 | 21.7 | 19.3 | 27.7 | – | 32.5 | 52±15 |
| Bleiziffer11 | 2012 | P, SC | SAPIEN /CoreValve | 06.2007–03.2009 | 227 | 81±7 | 7±5 | 21±14 | 52.0 | 18.5 | – | 26.9 | 18.1 | 22.9 | – |
| Buellesfeld12 | 2011 | P, MC | CoreValve | 2006–2009 | 126 | 81.9±6.4 | – | 23.4±13.8 | 65.9 | 26.2 | 23.8 | 19.1 | 22.2 | 23.0 | – |
| D'Onofrio13 | 2011 | P, MC | SAPIEN | 04.2008–09.2010 | 504 | 81.2±6.5 | 11.0±4.0 | 26.3±13.8 | 50.4 | 16.5 | 22.0 | 45.4 | – | 34.3 | 52.4±13.6 |
| Gasparetto14 | 2012 | P, SC | SAPIEN /CoreValve | 06.2007–04.2011 | 191 | 80.5±56.0 | – | 21.4±13.4 | 59.2 | 15.2 | 14.1 | – | 31.9 | 27.8 | 54.3±12.9 |
| Kalavrouziotis 15 | 2011 | P, SC | SAPIEN | 04.2007–07.2010 | 35 | 79.2±9.4 | 7.5±3.6 | 18.8±14.1 | 60.0 | 31.4 | 34.3 | – | 28.6 | 17.1 | 59±13 |
| Kodali1 | 2012 | RCT | SAPIEN | 05.2007–08.2009 | 348 | 83.6±6.8 | 11.8±3.3 | 29.3±16.5 | 74.7 | 42.5 | 33.3 | 42.8 | 27.6 | 43.7 | 52.5±13.5 |
| Makkar16 | 2012 | RCT | SAPIEN | 05.2007–03.2009 | 179 | 83.1±8.6 | 11.2±5.8 | 26.4±16.2 | 67.6 | 32.4 | 26.3 | 30.2 | 26.8 | 41.3 | 53.9±13.1 |
| Moat17 | 2011 | P, SC | SAPIEN /CoreValve | 01.2007–12.2009 | 870 | 81.9±7.1 | – | – | 47.1 | – | – | 29.0 | – | 28.7 | – |
| Ussia18 | 2012 | P, MC | CoreValve | 06.2007–08.2008 | 181 | 80.9±6.1 | 11.4±9.9 | 24.0±13.5 | 53.0 | 18.8 | 28.2 | 14.9 | – | 18.8 | – |
| Walther19 | 2012 | P, SC | SAPIEN | 02.2006–01.2010 | 299 | 82.1±6.4 | 12.0±7.7 | 31±15.8 | – | 28.1 | – | 47.2 | 18.7 | 43.1 | 55±14 |
| Wenaweser20 | 2011 | P, SC | SAPIEN /CoreValve | 07.2007–09.2010 | 257 | 82.1±6.2 | 6.4±5.0 | 24.7±24.9 | 65.0 | 21.0 | 22.6 | 24.9 | 9.0 | – | 51±14 |
| Ye21 | 2010 | P, SC | Cribier–Edwards/SAPIEN | 10.2005–02.2009 | 71 | 80.0±8.1 | 12.1±7.7 | 34.5±20.4 | 74.7 | 43.7 | 43.7 | 85.9 | 31.0 | 28.2 | – |
CABG, coronary artery bypass grafting; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; MC, multicenter; P, prospective; PCI, percutaneous coronary intervention; R, retrospective; RCT, randomised controlled trial; SC, single center; STS, Society of Thoracic Surgeons.